Sign in Sign up for free

Last updated: 2 January 2024 at 4:20pm EST

Paul Fonteyne Net Worth




The estimated Net Worth of Paul R. Fonteyne is at least $481 Thousand dollars as of 1 July 2022. Mr. Fonteyne owns over 8,275 units of AMAG Pharmaceuticals stock worth over $331,875 and over the last 5 years he sold AMAG stock worth over $0. In addition, he makes $149,452 as Independent Director at AMAG Pharmaceuticals.

Mr. Fonteyne AMAG stock SEC Form 4 insiders trading

Paul has made over 3 trades of the AMAG Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 8,275 units of AMAG stock worth $206,875 on 1 July 2022.

The largest trade he's ever made was exercising 8,275 units of AMAG Pharmaceuticals stock on 1 July 2022 worth over $206,875. On average, Paul trades about 1,142 units every 49 days since 2019. As of 1 July 2022 he still owns at least 13,275 units of AMAG Pharmaceuticals stock.

You can see the complete history of Mr. Fonteyne stock trades at the bottom of the page.





Paul Fonteyne biography

Paul Fonteyne serves as Independent Director of the Company. Prior to that role, Mr. Fonteyne served as the United States Country Managing Director and President and Chief Executive Officer of Boehringer Ingelheim from 2011 through 2018. Previously, Mr. Fonteyne served as Senior Corporate Vice President in Boehringer Ingelheim GmbH from 2009 to 2011. From 2003 to 2008 Mr. Fonteyne served as Executive Vice President, Head of Marketing and Sales for Prescription Medicines at Boehringer-Ingelheim Pharmaceuticals, Inc. Prior to his time with Boehringer-Ingelheim, Mr. Fonteyne held commercial leadership roles at Merck and Co. Inc. and Abbott Laboratories. Mr. Fonteyne has served on the board of ResTORbio, Inc., a publicly traded biopharmaceutical company, since 2017, and has been a member of the board of Ypsomed AG, a publicly traded medical technology company, since 2018. He also was recently (April 2020) elected to serve on the board of Apellis Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. He is currently a director of the private companies Gelesis, Inc., a biotechnology company, and DalCor, Inc., a pharmaceutical company. Mr. Fonteyne currently serves on the advisory board of the Brigham and Women's Hospital Lung Center and has previously served on the board of PhRMA (the leading pharmaceutical industry association). He also serves as Chair of the American Cancer Society Initiative for New England (CEOs against Cancer) and as a Special Advisor to Canaan Partners, a Venture Capital Fund dedicated to Health Care and Technology early stage venture investing. Mr. Fonteyne holds an MS in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University. Mr. Fonteyne joined the Board in connection with our entry into a settlement agreement with, inter alia, Caligan Partners LP ("Caligan"), Mr. Johnson and Mr. Fonteyne (the "Settlement Agreement").

What is the salary of Paul Fonteyne?

As the Independent Director of AMAG Pharmaceuticals, the total compensation of Paul Fonteyne at AMAG Pharmaceuticals is $149,452. There are 9 executives at AMAG Pharmaceuticals getting paid more, with Joseph Vittiglio having the highest compensation of $1,411,860.



How old is Paul Fonteyne?

Paul Fonteyne is 58, he's been the Independent Director of AMAG Pharmaceuticals since 2019. There are 5 older and 7 younger executives at AMAG Pharmaceuticals. The oldest executive at AMAG Pharmaceuticals, Inc. is Davey Scoon, 73, who is the Independent Director.

What's Paul Fonteyne's mailing address?

Paul's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.

Insiders trading at AMAG Pharmaceuticals

Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C...., and Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.



What does AMAG Pharmaceuticals do?

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.



What does AMAG Pharmaceuticals's logo look like?

AMAG Pharmaceuticals, Inc. logo

Complete history of Mr. Fonteyne stock trades at AMAG Pharmaceuticals, Apellis Pharmaceuticals Inc, resTORbio, and Covetrus

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
1 Jul 2022 CVET Covetrus, Inc. Paul R. Fonteyne
Director
 Option 8,275 $20.85 $172,534
1 Jul 2022
13,275 ↗
10 Aug 2021 CVET Covetrus, Inc. Paul R. Fonteyne
Director
 Buy 5,000 $23.24 $116,200
10 Aug 2021
5,000 ↗
8 May 2020 APLS Apellis Pharmaceuticals Inc Paul R. Fonteyne
Director
 Buy 5,000 $31.81 $159,050
8 May 2020
5,000 ↗


AMAG Pharmaceuticals executives and stock owners

AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: